Horizon Therapeutics (NASDAQ: HZNP)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Horizon Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Horizon Therapeutics Company Info
Horizon Therapeutics is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis pain and inflammatory diseases.
News & Analysis
Amgen's planned acquisition of Horizon could close in the first half of next year.
Three big drugmakers could be interested in acquiring Horizon.
The company released encouraging year-end guidance.
If production setbacks can be avoided, gains should be in sight.
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.
Horizon Therapeutics has a clear path to significant sales growth.
The biopharmaceutical company released its latest quarterly update.
Investors were pleased with the company’s latest quarterly update.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/27/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
HZNP earnings call for the period ending September 30, 2021.
HZNP earnings call for the period ending June 30, 2021.
HZNP earnings call for the period ending March 31, 2021.
HZNP earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.